Taxanes, past, present, and future impact on non-small cell lung cancer

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Taxanes are novel microtubule-stabilizing agents and have shown efficacy in non-small cell lung cancer (NSCLC) since the 1990s. Paclitaxel and docetaxel have been used either as single agents or in combination with a platinum compound. The newer generation albumin-bound taxane, nab-paclitaxel, has also shown similar efficacy in advanced NSCLC, both as a single agent and in combination with a platinum compound. Nab-paclitaxel, being Cremophor EL free, appears to have a better toxicity profile than paclitaxel. Taxane/platinum combinations still remain the foundation of treatment for advanced or metastatic NSCLC. Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. Oral formulations of paclitaxel and docetaxel are of great interest, but have yet to receive regulatory approval in this disease. The phase I-II trials have shown that these formulations are feasible in the clinical setting.

Original languageEnglish (US)
Pages (from-to)571-583
Number of pages13
JournalAnti-Cancer Drugs
Volume25
Issue number5
DOIs
StatePublished - Jun 1 2014

Fingerprint

docetaxel
Taxoids
Paclitaxel
Non-Small Cell Lung Carcinoma
Platinum Compounds
Excipients
Platinum
Microtubules
Albumins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

@article{3c7f0ec965114f5aadec81f2b4154561,
title = "Taxanes, past, present, and future impact on non-small cell lung cancer",
abstract = "Taxanes are novel microtubule-stabilizing agents and have shown efficacy in non-small cell lung cancer (NSCLC) since the 1990s. Paclitaxel and docetaxel have been used either as single agents or in combination with a platinum compound. The newer generation albumin-bound taxane, nab-paclitaxel, has also shown similar efficacy in advanced NSCLC, both as a single agent and in combination with a platinum compound. Nab-paclitaxel, being Cremophor EL free, appears to have a better toxicity profile than paclitaxel. Taxane/platinum combinations still remain the foundation of treatment for advanced or metastatic NSCLC. Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. Oral formulations of paclitaxel and docetaxel are of great interest, but have yet to receive regulatory approval in this disease. The phase I-II trials have shown that these formulations are feasible in the clinical setting.",
author = "Monika Joshi and Xin Liu and Chandra Belani",
year = "2014",
month = "6",
day = "1",
doi = "10.1097/CAD.0000000000000080",
language = "English (US)",
volume = "25",
pages = "571--583",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Taxanes, past, present, and future impact on non-small cell lung cancer. / Joshi, Monika; Liu, Xin; Belani, Chandra.

In: Anti-Cancer Drugs, Vol. 25, No. 5, 01.06.2014, p. 571-583.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Taxanes, past, present, and future impact on non-small cell lung cancer

AU - Joshi, Monika

AU - Liu, Xin

AU - Belani, Chandra

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Taxanes are novel microtubule-stabilizing agents and have shown efficacy in non-small cell lung cancer (NSCLC) since the 1990s. Paclitaxel and docetaxel have been used either as single agents or in combination with a platinum compound. The newer generation albumin-bound taxane, nab-paclitaxel, has also shown similar efficacy in advanced NSCLC, both as a single agent and in combination with a platinum compound. Nab-paclitaxel, being Cremophor EL free, appears to have a better toxicity profile than paclitaxel. Taxane/platinum combinations still remain the foundation of treatment for advanced or metastatic NSCLC. Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. Oral formulations of paclitaxel and docetaxel are of great interest, but have yet to receive regulatory approval in this disease. The phase I-II trials have shown that these formulations are feasible in the clinical setting.

AB - Taxanes are novel microtubule-stabilizing agents and have shown efficacy in non-small cell lung cancer (NSCLC) since the 1990s. Paclitaxel and docetaxel have been used either as single agents or in combination with a platinum compound. The newer generation albumin-bound taxane, nab-paclitaxel, has also shown similar efficacy in advanced NSCLC, both as a single agent and in combination with a platinum compound. Nab-paclitaxel, being Cremophor EL free, appears to have a better toxicity profile than paclitaxel. Taxane/platinum combinations still remain the foundation of treatment for advanced or metastatic NSCLC. Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. Oral formulations of paclitaxel and docetaxel are of great interest, but have yet to receive regulatory approval in this disease. The phase I-II trials have shown that these formulations are feasible in the clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=84892717638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892717638&partnerID=8YFLogxK

U2 - 10.1097/CAD.0000000000000080

DO - 10.1097/CAD.0000000000000080

M3 - Review article

C2 - 24463482

AN - SCOPUS:84892717638

VL - 25

SP - 571

EP - 583

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -